A targeted deep sequencing assay identifies multidrugresistant tuberculosis strains responsible for silent outbreaks

The new edition of the International Symposium on Microbial Ecology a staple meeting in the field, will cover many topics, in environment, human and animal health, and bioprocesses.

For over a decade, GenoScreen has been committed to the fight against tuberculosis (TB), one of the deadliest infectious diseases in the world. The company's journey began with the groundbreaking development of MIRU-VNTR typing kits in 2013 which marked a turning point in TB research and control by enabling rapid and accurate identification of TB strains. This breakthrough technology provided an unparalleled level of resolution in characterizing TB strains, essential for the management and control of TB outbreaks, allowing researchers and public health authorities to track the spread of the disease more efficiently and prevent further outbreaks.


Continuing on this innovation path, GenoScreen developed the Deeplex® Myc-TB assay, one of the most comprehensive CE-IVD kit to test drug susceptibility and resistance of Mycobacterium tuberculosis, the bacterium causing TB. The cutting-edge technology of this kit enables quicker and more accurate diagnosis of tuberculosis and its drug resistance, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). By providing physicians and researchers with a highly reliable and efficient diagnostic tool, GenoScreen helps to ensure that patients receive the best possible treatment and that the spread of TB is controlled as effectively as possible. The company is continuously striving for improvement and optimization, and is currently working on a new version of the kit, even more extensive.


GenoScreen's commitment to fight tuberculosis goes beyond the development and commercialization of innovative tools. They closely collaborate with genomics and healthcare leading companies such as Illumina or Cerba, NGOs and supranational reference labs to leverage the strengths of each entity, facilitating the implementation of innovative solutions in countries with the highest needs. Through these collaborations, GenoScreen and its employees contributes to the battle against TB and support the goal of the WHO to eradicate TB by 2035.


   “At GenoScreen, we consider investing in and getting involved in the fight against tuberculosis to be more than just our job, but part of our core values and mission. We believe that through our ongoing R&D, strategic partnerships, and unwavering dedication, we can help to finally eliminate this devastating infection and improve the lives of millions of people living with TB and other infectious diseases.” André Tordeux, CEO.


Yes we can, end TB!

Dr Philip Supply, Director of Research at the CNRS and Scientific Adviser at GenoScreen, has received the prestigious Gardner Middlebrook Lifetime Achievement Award at the 42nd Annual Congress of the European Society of Mycobacteriology (ESM) on 26 June 2022 in Bologna – Italy. This award recognizes his outstanding contribution to the study on the genomics of the tuberculosis bacillus, and to the development, in collaboration with GenoScreen, of the first next-generation sequencing test for the comprehensive detection of drug resistance directly from clinical specimens.

The Gardner Middlebrook Award honours scientists who have made important lifetime contributions in the study, diagnosis and treatment of tuberculosis. Introduced in 1996, the award is named after Gardner Middlebrook (1915-1986), a US physician, a renowned professor and world authority in the field of tuberculosis, who was director of research at the National Jewish Hospital in Denver, United States (1952-1964).

Dr Philip Supply works at the Center of Infection and Immunity, at the Pasteur Institute in Lille, France. He devotes his research to the genomics, the evolution and the molecular diagnosis of mycobacterial pathogens. Since 2006, he is also a Scientific Adviser for GenoScreen in molecular microbiology and microbial genomics.

This year's award was presented by Daniela Maria Cirillo, President of the European Society of Mycobacteriology since 2018 and Head of the Emerging Bacterial Pathogens Unit at the San Raffaele Hospital (IRCC) in Milan, Italy.

GenoScreen is now a certified service provider of Oxford Nanopore Technologies.

The program of this 42nd edition has for main topics Covid and Tuberculosis and will address new diagnostic strategies.

GenoScreen, world specialist in TB genomic solutions, and Illumina partner to expand access to a package combining Deeplex® Myc-TB assay and Illumina sequencing products.

 Meet us at the 32th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) from April 23th to 26th in Lisbon, Portugal.

By continuing your visit to this site, you accept the use of statistics cookies